Insiders Snap Up $54M in Biotech and Offshore Driller Stocks
John Davis ; 2025-10-28 07:31:03
In the past week or so, some public offerings of stock prompted big insider buying. Two were from biopharmaceutical companies riding high on strong trial results. Furthermore, an offshore driller was looking to pay down some debt. However, these were not the only notable purchases in that time.
24/7 Wall St. Key Points:
- In the past week or so, some public offerings of stock prompted huge insider buying.
- However, these were not the only notable insider purchases recently.
- Are you ahead, or behind on retirement? SmartAsset’s free tool can match you with a financial advisor in minutes to help you answer that today. Each advisor has been carefully vetted, and must act in your best interests. Don’t waste another minute; learn more here.(Sponsor)
Let’s take a quick look at these notable transactions in the past couple of weeks.
Is Insider Buying Important?
What does insider buying tell us?
A well-known adage reminds us that corporate insiders and 10% owners really only buy shares of a company because they believe the stock price will rise and they want to profit from it. Thus, insider buying can be an encouraging signal for potential investors. This is all the more so during times of uncertainty in the markets, and even when markets are near all-time highs.
With the second-quarter earnings-reporting season over, insiders are largely free to buy or sell shares until the next season begins. Below are some of the most notable insider purchases that were reported recently, starting with the largest and most prominent.
PepGen
Loading stock data...- Buyer(s):10% owner R.A. Capital Management
- Total shares:almost 9.4 million
- Price per share:$3.20
- Total cost:$30.0 million
This biotech-focused investment firm bought into a public offering of PepGen Inc. (NASDAQ: PEPG) shares as the Boston-based company released stellar trial results. The offering raised $115 million, with which PepGen intends to fund ongoing research and clinical development efforts.
The stock is more than 300% higher than a month ago and was last seen trading well above the offering price. However, the share price is still down about 45% year over year. But analysts on average see plenty of room to run, as their mean price target is up at $8.17 and their consensus recommendation is to buy shares.
Note that this owner also recently bought about $30 million worth of Mineralys Therapeutics Inc. (NASDAQ: MLYS).
Transocean
Loading stock data...- Buyer(s):a director
- Total shares:4.0 million
- Price per share:$3.05
- Total cost:$12.2 million
This transaction was also part of a public offering of stock, in this case to help Transocean Ltd. (NYSE: RIG) pay down debt. Shares retreated after the announcement but now are up more than 24% from 90 days ago. However, a year ago, the stock was trading around $4.50 a share.
The Swiss offshore driller has a mean price target of $3.88, signaling 20.1% upside in the next 12 months. Yet, of 13 analysts who cover the stock, only four recommend buying shares, including Barclays, which maintained its Overweight rating back in August.
Note that the buyer is also a beneficial owner and has a stake of almost 95.1 million shares.
MBX Biosciences
Loading stock data...- Buyer(s):a director
- Total shares:almost 666,700
- Price per share:$18.00
- Total cost:nearly $12.0 million
This clinical-stage biopharmaceutical company also had a public offering of shares. MBX Biosciences Inc. (NASDAQ: MBX) was looking to raise around $200 million, after shares surged following positive trial results for its thyroid disease treatment.
The stock is 44.7% higher than a month ago but still down 9.5% since the beginning of the year. Shares were last seen trading for less than the offering price. But analysts see lots of room to run, because their mean price target is all the way up at $60.29. All seven analysts who cover the stock recommend buying shares.
Note that this buyer also picked up some shares of Arcutis Biotherapeutics Inc. (NASDAQ: ARQT) this summer.
And Other Insider Buying
These were not the only notable insider purchases of the past week or so. Here’s a quick look at some others.
| Stock | Buyer | Shares | Price | Cost |
| Prospect Capital Corp. (NASDAQ: PSEC) | CEO and COO | over 2.0 M | $2.61 to $2.73 | over $5.4 M |
| Pattern Group Inc. (NASDAQ: PTRN) | 10% owner | almost 302,300 | $12.00 to $13.49 | over $3.8 M |
| Opendoor Technologies Inc. (NASDAQ: OPEN) | a director | almost 300,800 | $6.65 | $2.0 M |
Recently, some smaller insider buying was reported at Agree Realty, AIG, Atlassian, Carmax, CME, Cooper Companies, Simon Property Group, WK Kellogg, and Worthington Enterprises as well.
Insiders Buy Over $98 Million in Biotech and Cybersecurity Shares in IPOs